For reprint rights or to purchase a copy of your Daily Journal photo, email jeremy@reprintpros.com for prices or call 949-702-5390.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Top 10 Most Read

Commission on Judicial Appointments confirms 3 justices to courts of appeal

May 15, 2024

FBI believed Feuer 'obstructed justice' in litigation investigation, documents show

May 16, 2024

9th Circuit strikes down felon's firearm conviction

May 10, 2024

Biden’s proposed tax increases will hurt, especially in California

May 15, 2024

Governor Newsom's revised budget cuts $97M from trial courts

May 10, 2024

DA transfers Grossman murder case after internal conflict allegation

May 14, 2024

'You have been sued' - and other unwitting insults of the procedural divorce

May 10, 2024

Non-compete covenants leave sports betting executive idle

May 16, 2024

California prison officials lose bid for qualified immunity in COVID-19 case

May 14, 2024

Against the 'Europeanization' of California's antitrust law

May 15, 2024

Mergers & Acquisitions

Aug. 19, 2003

Skadden Arps Guides SangStat in Buyout

Biotechnology company Genzyme Corp. is buying Fremont-based SangStat Medical Corp., which sells a lucrative drug for kidney-transplant patients.

By Toni Vranjes
        Biotechnology company Genzyme Corp. is buying Fremont-based SangStat Medical Corp., which sells a lucrative drug for kidney-transplant patients.
        The deal, valued at $600 million in cash, is the latest in a series of large biotech mergers. Earlier this year, Biogen Inc. and Idec Pharmaceuticals Corp. announced a $6.4 ...

To continue reading, please subscribe.

Already a subscriber?

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.